Q2 FY2026 · ended Jun 30, 2026 · Revenue $76,156, -96.6% YoY · Filed Aug 14, 2026
BioNexus Gene Lab Corp. (BGLC) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $76,156 and a net loss of $286,451. Free cash flow was -$422,741. As of Jun 30, 2026 it held $1.2 million in cash and investments and $198,585 in total debt.
Revenue
$76,156
-96.6% vs year-ago quarter
Net income
$-286,451
+53.5% vs year-ago quarter
Operating cash flow
$-422,491
+42.7% vs year-ago quarter
Free cash flow
$-422,741
+44.3% vs year-ago quarter
EPS
$-0.12
+65.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.93M
+63.3% vs year-ago quarter
Net cash
$1.03M
Q2 FY2026
Operating margin
-81.8%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BGLC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Kuala Lumpur
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1737523
- Former names
- BioNexus Gene Lab Coporation (until May 8, 2020)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $76,156 | $22,842 | $483,760 | $2.5M | $2.3M |
| Operating income | -$282,396 | -$540,490 | -$1.0M | -$702,509 | -$611,293 |
| Net income | -$286,451 | -$543,575 | -$1.0M | -$708,991 | -$616,172 |
| Diluted EPS | -$0.12 | -$0.23 | — | -$0.40 | -$0.34 |
| Operating cash flow | -$422,491 | -$147,671 | $961,062 | -$1.2M | -$737,907 |
| Free cash flow | -$422,741 | -$147,996 | $960,085 | -$1.2M | -$759,366 |
| Total assets | $8.7M | $9.0M | $9.3M | $7.6M | $9.4M |
| Total liabilities | $947,981 | $946,877 | $637,856 | $804,966 | $1.9M |
| Stockholders' equity | $7.8M | $8.1M | $8.6M | $6.8M | $7.5M |
| Cash and investments | $1.2M | — | $2.4M | — | — |
| Total debt | $198,585 | $216,428 | $176,046 | $183,746 | $197,156 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 7, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 14, 2026 | Dec 31, 2025 |
All 157 BioNexus Gene Lab Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.